Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov 19:2:411-27.
doi: 10.2147/IJWH.S7012.

Clinical trials and progress with paclitaxel in ovarian cancer

Sanjeev Kumar  1 , Haider Mahdi, Christopher Bryant, Jay P Shah, Gunjal Garg, Adnan Munkarah
Affiliations

Clinical trials and progress with paclitaxel in ovarian cancer

Sanjeev Kumar et al. Int J Womens Health. .

Abstract

Paclitaxel is a front-line agent for ovarian cancer chemotherapy, along with the platinum agents. Derived from the Pacific yew tree, Taxus brevifolia, paclitaxel has covered significant ground from the initial discovery of its antineoplastic properties to clinical applications in many forms of human cancers, including ovarian cancer. Although much has been published about the unique mechanism of action of this agent, several issues remain to be resolved. Finding the appropriate dosage schedule for paclitaxel in chemo-naïve and recurrent ovarian cancer, defining the role of paclitaxel in maintenance chemotherapy, and elucidating the mechanisms of taxane resistance are areas of intense research. Newer forms of taxanes are being manufactured to avoid troublesome adverse effects and to improve clinical efficacy. These issues are reviewed in detail in this paper with an emphasis on clinically relevant evidence-based information.

Keywords: clinical trials; ovarian cancer; paclitaxel; treatment.

PubMed Disclaimer

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Goodman MT, Howe HL, Tung KH, et al. Incidence of ovarian cancer by race and ethnicity in the United States, 1992–1997. Cancer. 2003;97:2676–2685. - PubMed
    1. Chiaffarino F, Parazzini F, Bosetti C, et al. Risk factors for ovarian cancer histotypes. Eur J Cancer. 2007;43:1208–1213. - PubMed
    1. Soegaard M, Jensen A, Hogdall E, et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: Results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev. 2007;16:1160–1166. - PubMed
    1. Chan JK, Urban R, Cheung MK, et al. Ovarian cancer in younger vs older women: A population-based analysis. Br J Cancer. 2006;95:1314–1320. - PMC - PubMed